Quick answer
The kidney tumor pathology report describes the specimen removed at surgery. It gives the tumor type under the 2022 WHO classification, the ISUP grade, the size, the pT stage, the margin and features such as necrosis and a sarcomatoid component.1 The most common cancers are clear cell, papillary and chromophobe carcinoma, and the most common benign tumors are oncocytoma and angiomyolipoma.1 From these findings, the European guideline sorts the risk into low, intermediate and high, and the risk sets the schedule of follow-up scans.8
What the report says and what it means
In a partial nephrectomy, the tumor comes out with a rim of healthy tissue and goes to pathology. Besides the type, the report covers the grade, any sarcomatoid component, vascular invasion, necrosis, invasion of the collecting system and of the fat around the kidney, and the pT stage.1
| On the report | What it means |
|---|---|
| Histological type | The kind of tumor seen under the microscope, such as clear cell, papillary or chromophobe carcinoma, or oncocytoma1 |
| ISUP grade (or WHO/ISUP) | From 1 to 4, how far the cell nuclei depart from normal. Not used for chromophobe carcinoma3 |
| Size and pT | The largest diameter of the tumor and how far it reached4 |
| Margin | Whether tumor reaches the edge of the removed tissue. Positive means tumor cells at the edge7 |
| Fat invasion | Tumor reaching the fat around the kidney or the renal sinus fat, near the vessels. It moves the stage to pT3a4 |
| Renal vein invasion | Tumor inside the renal vein or its branches. Also pT3a4 |
| Tumor necrosis | Areas of dead tissue inside the tumor. It counts in the risk score3,6 |
| Sarcomatoid or rhabdoid component | Areas where the tumor loses its original pattern and behaves more aggressively. Equivalent to grade 45 |
| pNx, pN0 or pN1 | pNx when no lymph nodes were removed, pN0 when they were free, pN1 when at least one had cancer4 |
The most common types of kidney cancer
The 2022 WHO classification now defines some rare tumors by the altered gene, not only by how they look under the microscope.2 Most patients, though, have one of the three main types.1
- Clear cell: about 70% of renal cell carcinomas.1
- Papillary: the second most common, 13% to 20% of epithelial kidney tumors. It is no longer split into type 1 and type 2.1
- Chromophobe: about 5% of cases.10 It is now grouped with oncocytoma among the oncocytic and chromophobe tumors.1
The type carries prognostic information, but the difference disappears when tumors of the same stage are compared.5 That is why the report is read as a whole. The 2022 classification also lists multilocular cystic renal neoplasm of low malignant potential, a subtype of clear cell carcinoma made only of cysts. It is considered benign, with no reports of progression on long follow-up.1
When the report shows a benign tumor
Oncocytoma accounts for 4% to 7% of solid kidney tumors and 30% of benign masses removed at surgery. CT and MRI cannot reliably tell it apart from cancer. The 2022 WHO classification does not allow a definitive diagnosis of oncocytoma on a needle biopsy, because chromophobe carcinoma can have very similar areas.1
Classic angiomyolipoma, made of fat, muscle and vessels, is completely benign. A rare variant, epithelioid angiomyolipoma, can behave aggressively.1 The page on angiomyolipoma explains when it is only monitored and when it is treated.
ISUP grade and sarcomatoid component
The four-tier WHO/ISUP grade replaced the older Fuhrman grade.1 It applies to clear cell and papillary carcinoma. Grades 1 to 3 depend on how visible the nucleolus is. Grade 4 is given when nuclei are markedly abnormal or there is a sarcomatoid or rhabdoid component.3 Chromophobe carcinoma is not graded.3,5
A sarcomatoid component is an area where the tumor loses the features of its original type, and it is linked to a worse outlook in any type of renal cell carcinoma.1 There is no minimum amount for it to be reported, and the pathologist should also report the underlying type.3 The larger the sarcomatoid area, the worse the survival. A cut-off of 20% has been proposed to separate focal from extensive involvement.5
pT stage: size and how far the tumor reached
The "p" stands for pathological: the stage measured on the removed specimen, not on scans. The system used is the 2017 TNM classification.4
| On the report | What it means |
|---|---|
| pT1a | Up to 4 cm, confined to the kidney4 |
| pT1b | From 4 to 7 cm, confined to the kidney4 |
| pT2a and pT2b | From 7 to 10 cm (pT2a) or over 10 cm (pT2b), confined to the kidney4 |
| pT3a | Extends into the renal vein or its branches, the collecting system, the fat around the kidney or the renal sinus fat, without going beyond Gerota's fascia4 |
| pT3b and pT3c | Extends into the vena cava below the diaphragm (pT3b), or above it or into the wall of the vena cava (pT3c)4 |
| pT4 | Goes beyond Gerota's fascia, the layer that wraps the kidney, or reaches the adrenal gland on the same side4 |
Renal sinus fat invasion may carry a worse outlook than invasion of the fat around the kidney, but both are staged as pT3a.4 The International Society of Urological Pathology (ISUP) consensus agreed that invasion of small vessels, seen only under the microscope, does not change the stage.3
When scans show no enlarged lymph nodes, the European guideline only justifies removing them if they are seen or felt during surgery.7 That is why many partial nephrectomy reports say pNx, meaning the lymph nodes were not assessed.4
Surgical margin
A positive margin occurs in about 2% to 8% of partial nephrectomies for T1 tumors. It is more frequent when partial surgery is the only way to preserve kidney function, as with a solitary kidney or tumors in both kidneys, and in pT2a, pT3a or grade 3 and 4 tumors.7
Only some of these patients have disease left behind. Local recurrence was 16% with a positive margin and 3% with a negative one.7 A negative margin is no full guarantee either: recurrence has been reported in up to 1.5% of those cases.7
For a microscopic positive margin, the European guideline does not recommend re-resection or removal of the whole kidney, since that can mean overtreatment in many cases. It recommends more frequent imaging, especially when a tumor that looked T1 on scans turns out pT3a on the report.7 The other risks of the operation are on partial nephrectomy complications.
From the report to a risk group
For clear cell carcinoma, the European guideline recommends the 2003 Leibovich score.5,8 It was built from 1,671 patients and uses five findings from the report: stage, lymph nodes, size, grade and necrosis.6
| Report item | Points |
|---|---|
| Stage | pT1a: 0; pT1b: 2; pT2: 3; pT3 or pT4: 45 |
| Lymph nodes | pNx or pN0: 0; pN1: 25 |
| Size | Under 10 cm: 0; 10 cm or more: 15 |
| Grade | 1 or 2: 0; 3: 1; 4: 35 |
| Necrosis | Absent: 0; present: 15 |
A total of 0 to 2 is low risk, 3 to 5 is intermediate risk, and 6 or more is high risk.5 For other types, the guideline's follow-up table uses stage and grade.8
A pT1a tumor of grade 1 or 2 without necrosis, for example, scores zero. After surgery for low-grade T1a tumors, the outcome is almost always excellent.8
What changes in follow-up
The European guideline recommends basing follow-up on the risk of recurrence. Its proposed schedule rests on expert opinion and uses CT of the chest and abdomen; MRI of the abdomen can replace the abdominal CT.8
| Group | How it is defined | Scans |
|---|---|---|
| Low risk | Clear cell: Leibovich 0 to 2. Other types: pT1a or pT1b, pNx or pN0, grade 1 or 2 | At 6, 18 and 30 months, then every 2 years. After 3 years, stopping imaging can be discussed8 |
| Intermediate risk | Clear cell: Leibovich 3 to 5. Other types: pT1b with pNx or pN0, or grade 3 or 4 | At 6, 12, 24 and 36 months, then once a year up to 5 years and every 2 years after8 |
| High risk | Clear cell: Leibovich 6 or more. Other types: pT2 to pT4, or pN1, any grade | At 3, 6, 12, 18, 24 and 36 months, then once a year up to 5 years and every 2 years after8 |
In my practice, follow-up is a CT or MRI of the abdomen every 6 months for 5 years.
In every group, follow-up also looks after kidney and heart function for as long as needed.8 A positive margin moves the patient to a more frequent schedule.7,8 A tumor in the other kidney is rare (1% to 2%) and can appear years later; found early, it can be treated while preserving the kidney again.8
When treatment after surgery comes up
For clear cell carcinoma at higher risk of recurrence, the European guideline recommends offering pembrolizumab, an immunotherapy drug, preferably 12 to 16 weeks after surgery and after restaging scans. The criteria are those of the KEYNOTE-564 study: pT2 with grade 4 or a sarcomatoid component, pT3 of any grade, pT4, involved lymph nodes, or metastases removed within one year of surgery.7 pT1 tumors without lymph node involvement fall outside these criteria and continue with follow-up alone after surgery.
In KEYNOTE-564, 994 patients received pembrolizumab or placebo for about one year. At five years, 60.9% were disease-free with the drug and 52.2% with placebo. Estimated survival was 87.7% and 82.3%, respectively.9
The same guideline asks that patients know about side effects. Severe adverse events from any cause occurred in 32% with the drug and 18% with placebo. It also asks that the trials of other immunotherapy drugs, which showed no benefit, be part of the conversation, and it notes the risk of treating people who would not need it. Radiotherapy after surgery has not been shown to improve survival.7
How I approach it
I have performed robotic partial nephrectomy since 2020. At the consultation after surgery, I go through the report with you, item by item, alongside the scans from before the operation. From there we define the risk group and the schedule of scans. If the report meets the criteria for treatment after surgery, we talk through the benefits, the side effects and the other options, and we decide together.
If you were operated on by another surgeon and want to understand your report, the consultation can be online, in English, with the report and scans sent in advance. The online consultation page explains how to book. The overview of the disease is on kidney cancer.
When to see a urologist
- If you have received the report and have not yet discussed it with your doctor
- If the report mentions a positive margin, a sarcomatoid component or pT3
- If you are unsure how often to have scans
- If a biopsy suggested oncocytoma and you want to understand what to do
Frequently asked questions
What does clear cell carcinoma mean on the report?+
It is the most common type of kidney cancer, about 70% of cases.1 The type alone does not decide what comes next. Grade, stage and necrosis also count toward the risk.5
What is the ISUP grade of a kidney tumor?+
It is a scale from 1 to 4 that measures how far the nuclei of the tumor cells depart from normal. Grades 1 to 3 depend on how visible the nucleolus is, and grade 4 is given when nuclei are markedly abnormal or there is a sarcomatoid or rhabdoid component.3 The grade applies to clear cell and papillary carcinoma. Chromophobe carcinoma is not graded.3,5
What does pT1a mean on a kidney report?+
It means a tumor up to 4 cm, confined to the kidney. pT1b goes from 4 to 7 cm, and pT3a means the tumor reached the fat around the kidney, the renal vein or the collecting system, which drains the urine.4
Does a positive margin after partial nephrectomy mean cancer was left behind?+
Not always. A positive margin occurs in about 2% to 8% of partial nephrectomies for T1 tumors. Local recurrence was 16% with a positive margin and 3% with a negative one. For a microscopic positive margin, the European guideline does not recommend routine further surgery and asks for more frequent imaging.7
My report says oncocytoma. Is it cancer?+
No. Oncocytoma is a benign tumor and accounts for 4% to 7% of solid kidney tumors. Under the 2022 WHO classification, the diagnosis is made on the surgical specimen, not on a needle biopsy.1
Will I need treatment after kidney surgery?+
For pT1 tumors without lymph node involvement, no. The European guideline recommends offering pembrolizumab after surgery for clear cell carcinoma at higher risk of recurrence, using the KEYNOTE-564 criteria, such as pT2 with grade 4, pT3, pT4 or involved lymph nodes.7 In that study, estimated five-year survival was 87.7% with the drug and 82.3% with placebo.9
Who can explain my kidney tumor pathology report in Brazil?+
I go through the report item by item in a consultation, in person or online and in English, also for patients operated on by another surgeon. I am Dr. Petronio Melo, a urologist and robotic surgeon in São Paulo, Brazil, CRM-SP 157.598 and RQE 70.275. I have performed robotic partial nephrectomy since 2020. I have done more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic, on the da Vinci X and da Vinci Xi platforms. The first consultation can be online, with the report and scans sent in advance.
References
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Epidemiology, aetiology and pathology chapter. EAU
- Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2022;82(5):458-468. PubMed
- Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490-1504. PubMed
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Staging and classification systems chapter. EAU
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Prognostic factors chapter. EAU
- Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-1671. PubMed
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Disease management chapter. EAU
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Follow-up chapter. EAU
- Haas NB, Powles TB, Tomczak P, et al. Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study. Ann Oncol. 2026;37(11):1564-1571. PubMed
- Vera-Badillo FE, Conde E, Duran I. Chromophobe renal cell carcinoma: a review of an uncommon entity. Int J Urol. 2012;19(10):894-900. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation
